Kineta Announces Participation at October Investor Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/22/2026

1. WMT
2. ROST
3. AAP
4. SPY
5. NVDA

6. AVGO
7. SPCX
8. DE
9. OSIS
10. REAX

Get Alerts KA Hot Sheet

Price: $0.57 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

SEATTLE, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today its participation in the following upcoming investor conferences in October 2023.

JonesTrading 2023 Healthcare Summit Format: Investor meetingsLocation: Miami, FLDate: October 9-11, 2023

BIO Investor ForumFormat: Corporate presentation and investor meetingsLocation: San Francisco, CADate: Tuesday, October 17, 2023Time: 1:15-2:00 P.M. Pacific Time

OPAL Group Family Office & Private Wealth Management Forum West 2023Format: Corporate presentation and investor meetingsLocation: Napa, CADate: Thursday, October 19, 2023Time: 10:50-11:10 P.M. Pacific Time

About KinetaKineta (Nasdaq: KA) is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the major challenges with current cancer therapy. The company’s immuno-oncology pipeline includes KVA12123, a novel VISTA blocking immunotherapy currently in a Phase 1/2 clinical trial in patients with advanced solid tumors, and a preclinical monoclonal antibody targeting CD27. For more information on Kineta, please visit www.kinetabio.com, and follow Kineta on Twitter, LinkedIn and Facebook.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Kineta, Inc.:Jacques BouchyEVP Investor Relations & Business Development +1 206-378-0400[email protected]

Investor Relations:John MullalyLifeSci Advisors, LLC[email protected]

Source: Kineta, Inc.